Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
Authors
Keywords
Nintedanib, Pirfenidone, Early termination, Adverse event, Anorexia, Weight loss
Journal
BMC Pulmonary Medicine
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-04-11
DOI
10.1186/s12890-019-0841-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
- (2018) Carlo Vancheri et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients
- (2018) Yoshinari Nakatsuka et al. RESPIRATION
- Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
- (2017) Steven D Nathan et al. Lancet Respiratory Medicine
- Idiopathic pulmonary fibrosis
- (2017) Fernando J. Martinez et al. Nature Reviews Disease Primers
- Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
- (2017) Satoshi Ikeda et al. Scientific Reports
- Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
- (2016) Paola Rogliani et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
- (2016) Steven D Nathan et al. THORAX
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- (2015) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF
- (2015) Katrin Milger et al. EUROPEAN RESPIRATORY JOURNAL
- Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
- (2014) Takashi Ogura et al. EUROPEAN RESPIRATORY JOURNAL
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
- (2014) Dominique Valeyre et al. RESPIROLOGY
- The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis
- (2014) Samy Suissa et al. THORAX
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
- (2011) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started